Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Amortization of Deferred Charges (2023 - 2025)

Historic Amortization of Deferred Charges for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to -$375000.0.

  • Compass Therapeutics' Amortization of Deferred Charges fell 3489.21% to -$375000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$747000.0, marking a year-over-year increase of 6593.71%. This contributed to the annual value of -$1.7 million for FY2024, which is 4882.21% up from last year.
  • Per Compass Therapeutics' latest filing, its Amortization of Deferred Charges stood at -$375000.0 for Q3 2025, which was down 3489.21% from -$128000.0 recorded in Q2 2025.
  • In the past 5 years, Compass Therapeutics' Amortization of Deferred Charges ranged from a high of $26000.0 in Q1 2025 and a low of -$1.0 million during Q2 2023
  • For the 3-year period, Compass Therapeutics' Amortization of Deferred Charges averaged around -$486727.3, with its median value being -$376000.0 (2024).
  • Examining YoY changes over the last 5 years, Compass Therapeutics' Amortization of Deferred Charges showed a top increase of 10691.49% in 2025 and a maximum decrease of 3489.21% in 2025.
  • Compass Therapeutics' Amortization of Deferred Charges (Quarter) stood at -$812000.0 in 2023, then soared by 66.75% to -$270000.0 in 2024, then crashed by 38.89% to -$375000.0 in 2025.
  • Its last three reported values are -$375000.0 in Q3 2025, -$128000.0 for Q2 2025, and $26000.0 during Q1 2025.